__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
PIQRAY® (alpelisib) is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine-based therapy.1
PIQRAY® is given in combination with fulvestrant.1
Dosing and administration1
Continue treatment until disease progression or until unacceptable toxicity occurs.
Accounting for missed PIQRAY® doses1
- If a dose is missed, it can be taken immediately following food and within 9 hours after the time it is usually administered. After more than 9 hours, the dose should be skipped for that day. The next day, PIQRAY® should be taken at its usual time
- If the patient vomits after taking the dose, the patient should not take an additional dose on that day, and should resume the usual dosing schedule the next day at the usual time
Certain AEs may require dose modifications1
Caution should be used in patients with severe renal impairment as there is no experience with PIQRAY® in this population.
THERAPY MANAGEMENT GUIDE
Please see the therapy management guide for more details on dosing and administration.
The blister pack is designed to help patients stay on track with treatment1
*Tablets should not be chewed, crushed or split prior to swallowing. No tablet should be ingested if it is broken, cracked, or otherwise not intact.
AE, adverse event.
Reference
- PIQRAY® (alpelisib) Summary of Product Characteristics.
